Published in Eur J Heart Fail on June 05, 2010
Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol (2012) 2.47
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med (2010) 2.21
Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol (2013) 2.00
Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J (2012) 1.55
Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). JACC Heart Fail (2015) 1.46
Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail (2011) 1.45
Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol (2011) 1.44
Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol (2013) 1.06
Novel biomarkers in chronic heart failure. Nat Rev Cardiol (2012) 1.06
Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc (2012) 1.04
Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol (2012) 1.01
Positioning of inflammatory biomarkers in the heart failure landscape. J Cardiovasc Transl Res (2013) 0.93
Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail (2013) 0.91
Galectin 3 and incident atrial fibrillation in the community. Am Heart J (2014) 0.91
Biomarkers in acute heart failure--state of the art. Nat Rev Cardiol (2012) 0.87
Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc (2014) 0.87
Clinical adoption of prognostic biomarkers: the case for heart failure. Prog Cardiovasc Dis (2012) 0.85
Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study. Am Heart J (2014) 0.83
Predicting mortality in patients with acute heart failure: Role of risk scores. World J Cardiol (2015) 0.83
Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension. Heart Vessels (2015) 0.82
Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers (2012) 0.82
Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. Acad Emerg Med (2014) 0.82
Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev (2014) 0.81
Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Heart Rhythm (2014) 0.81
Galectin-3 in heart failure: more answers or more questions? J Am Heart Assoc (2012) 0.81
Acute heart failure: patient characteristics and pathophysiology. Curr Heart Fail Rep (2013) 0.80
Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail (2013) 0.80
Novel renal biomarkers to assess cardiorenal syndrome. Curr Heart Fail Rep (2014) 0.80
Galectin-3 Is Elevated and Associated With Adverse Outcomes in Patients With Single-Ventricle Fontan Circulation. J Am Heart Assoc (2016) 0.78
Biomarkers in cardiology--part 1--in heart failure and specific cardiomyopathies. Arq Bras Cardiol (2014) 0.78
Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure. Int J Med Sci (2014) 0.78
Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure. Biomed Res Int (2014) 0.78
Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. BMC Cardiovasc Disord (2016) 0.77
Recent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapies. Clin Med Insights Cardiol (2015) 0.77
Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes. Crit Care (2015) 0.76
Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Fail Clin (2012) 0.76
Can biomarkers help to diagnose early heart failure with preserved ejection fraction? Dis Markers (2015) 0.76
Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Curr Heart Fail Rep (2017) 0.75
Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve. BMC Cardiovasc Disord (2017) 0.75
Role of galectin-3 and plasma B type-natriuretic peptide in predicting prognosis in discharged chronic heart failure patients. Medicine (Baltimore) (2016) 0.75
Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction. Dis Markers (2016) 0.75
Cellular, molecular, genomic changes occurring in the heart under mechanical circulatory support. Ann Cardiothorac Surg (2014) 0.75
Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling. Heart Lung Circ (2016) 0.75
Right Atrium Volume Index in Patients with Secondary Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2015) 0.75
Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure. Int Cardiovasc Res J (2014) 0.75
Alternative Biomarkers for Combined Biology. Heart Fail Clin (2017) 0.75
Galectin-3 Serum Levels Are Independently Associated With Microalbuminuria in Chronic Heart Failure Outpatients. Res Cardiovasc Med (2015) 0.75
Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients. Cancer Chemother Pharmacol (2015) 0.75
Galectin-3: A Link between Myocardial and Arterial Stiffening in Patients with Acute Decompensated Heart Failure? Arq Bras Cardiol (2016) 0.75
Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med (2016) 0.75
Impact of aortic stiffness on survival in end-stage renal disease. Circulation (1999) 7.17
Biomarkers in heart failure. N Engl J Med (2008) 5.20
The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol (2005) 3.85
Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J (2004) 3.52
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J (2005) 2.93
Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol (2008) 2.83
Cardiac troponin and outcome in acute heart failure. N Engl J Med (2008) 2.41
Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol (2006) 2.29
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol (2008) 1.94
Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail (2009) 1.93
Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol (2007) 1.92
Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant (2008) 1.52
Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol (2008) 1.51
Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart (2008) 1.28
Role of galectin-3 in human pulmonary fibrosis. Allergol Int (2007) 1.24
NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J (2006) 0.99
Vascular function assessed with cardiovascular magnetic resonance predicts survival in patients with advanced chronic kidney disease. J Cardiovasc Magn Reson (2008) 0.95
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
Recommendations for chamber quantification. Eur J Echocardiogr (2006) 11.39
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med (2015) 8.70
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13
N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation (2007) 3.97
Partial thrombosis of the false lumen in patients with acute type B aortic dissection. N Engl J Med (2007) 3.92
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Cardiovascular screening in college athletes with and without electrocardiography: A cross-sectional study. Ann Intern Med (2010) 3.39
Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med (2007) 3.31
Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem (2002) 3.22
Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82
QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics (2013) 2.80
Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging (2012) 2.72
Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr (2013) 2.71
Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol (2005) 2.62
Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol (2008) 2.59
Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med (2006) 2.57
Long-term survival in patients presenting with type B acute aortic dissection: insights from the International Registry of Acute Aortic Dissection. Circulation (2006) 2.56
Myocardial injury and ventricular dysfunction related to training levels among nonelite participants in the Boston marathon. Circulation (2006) 2.40
Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol (2008) 2.36
Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol (2005) 2.34
Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail (2010) 2.32
Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol (2006) 2.29
Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res (2004) 2.29
Red blood cell distribution width and 1-year mortality in acute heart failure. Eur J Heart Fail (2009) 2.28
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J (2008) 2.26
Gender-related differences in acute aortic dissection. Circulation (2004) 2.24
Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol (2009) 2.18
Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J (2006) 2.14
Cardiomyocyte-specific overexpression of nitric oxide synthase 3 prevents myocardial dysfunction in murine models of septic shock. Circ Res (2006) 2.02
Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J (2006) 1.98
Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation (2012) 1.95
Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol (2011) 1.93
Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail (2011) 1.92
Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med (2004) 1.92
Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol (2007) 1.92
Persistent and reversible cardiac dysfunction among amateur marathon runners. Eur Heart J (2006) 1.88
Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol (2009) 1.87
Left ventricular lead electrical delay predicts response to cardiac resynchronization therapy. Heart Rhythm (2006) 1.87
Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation (2005) 1.86
Multimodality imaging of pericardial diseases. JACC Cardiovasc Imaging (2010) 1.84
Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J (2006) 1.81
Long-term survival after surgical revascularization for moderate ischemic mitral regurgitation. Ann Thorac Surg (2005) 1.77
Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J (2008) 1.75
Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation (2009) 1.74
Biomarkers of cardiovascular stress and incident chronic kidney disease. Clin Chem (2013) 1.71
Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol (2013) 1.69
Detection of depression in cardiac inpatients: feasibility and results of systematic screening. Am Heart J (2010) 1.68
Impact of segmental left ventricle lead position on cardiac resynchronization therapy outcomes. Heart Rhythm (2010) 1.66
Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay. Clin Chim Acta (2009) 1.65
An educational intervention reduces the rate of inappropriate echocardiograms on an inpatient medical service. JACC Cardiovasc Imaging (2013) 1.65
Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol (2005) 1.63
Observations from non-invasive measures of right heart hemodynamics in left ventricular assist device patients. J Am Soc Echocardiogr (2009) 1.62
Blood pressure and left ventricular hypertrophy during American-style football participation. Circulation (2013) 1.60
Differences in cardiac parameters among elite rowers and subelite rowers. Med Sci Sports Exerc (2010) 1.60
Biomarker evidence of myocardial cell injury is associated with mortality in acute respiratory distress syndrome. Crit Care Med (2007) 1.59
Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol (2005) 1.58
Can a teaching intervention reduce interobserver variability in LVEF assessment: a quality control exercise in the echocardiography lab. JACC Cardiovasc Imaging (2011) 1.58
Inhaled nitric oxide decreases infarction size and improves left ventricular function in a murine model of myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2006) 1.57
Changes in mitral regurgitation after replacement of the stenotic aortic valve. Ann Thorac Surg (2008) 1.57
Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J (2012) 1.55
Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol (2013) 1.55
Emerging biomarkers in heart failure. Clin Chem (2011) 1.54
Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol (2009) 1.54
Postoperative troponin-T predicts prolonged intensive care unit length of stay following cardiac surgery. Crit Care Med (2004) 1.53
Differential left ventricular remodelling and longitudinal function distinguishes low flow from normal-flow preserved ejection fraction low-gradient severe aortic stenosis. Eur Heart J (2013) 1.52
Mechanism of decrease in mitral regurgitation after cardiac resynchronization therapy: optimization of the force-balance relationship. Circ Cardiovasc Imaging (2009) 1.52
Evolving trends in the use of echocardiography: a study of Medicare beneficiaries. J Am Coll Cardiol (2007) 1.52
Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome. Crit Care Med (2008) 1.52
Training-specific changes in cardiac structure and function: a prospective and longitudinal assessment of competitive athletes. J Appl Physiol (1985) (2007) 1.50
Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation. J Am Soc Echocardiogr (2009) 1.49
Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J (2012) 1.48
Echocardiographic measures of acute haemodynamic response after cardiac resynchronization therapy predict long-term clinical outcome. Eur Heart J (2007) 1.48
Images in cardiovascular medicine. Covered stent septal ablation for hypertrophic obstructive cardiomyopathy: initial success but ultimate failure resulting from collateral formation. Circulation (2003) 1.47
Single resting hsTnT level predicts abnormal myocardial stress test in acute chest pain patients with normal initial standard troponin. JACC Cardiovasc Imaging (2013) 1.46
Performance of the 2010 European Society of Cardiology criteria for ECG interpretation in athletes. Heart (2011) 1.45
Natriuretic peptide testing in heart failure. Circulation (2011) 1.44
Mutant mouse models reveal the relative roles of E2F1 and E2F3 in vivo. Mol Cell Biol (2002) 1.44
Activated leukocyte cell adhesion molecule and prognosis in acute ischemic stroke. Stroke (2011) 1.44
Comparison of the 2008 and 2011 appropriate use criteria for stress echocardiography. J Am Soc Echocardiogr (2013) 1.43
Biology of the natriuretic peptides. Am J Cardiol (2008) 1.41
Non-ST segment elevation acute coronary syndromes: A comprehensive review. South Med J (2006) 1.40
The impact of endurance exercise training on left ventricular torsion. JACC Cardiovasc Imaging (2010) 1.40
[Comparative prognostic value of plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute destabilized heart failure]. Rev Esp Cardiol (2011) 1.39